The future of fertility
Ovelle is developing a new way to produce human eggs from a woman’s own cells, opening a path to parenthood for women who cannot produce viable eggs today.
Ovelle is a research-stage biotechnology company. Our technology is not yet available for clinical use.
The opportunity
The limitation
IVF depends on the eggs a woman can produce. For women who cannot produce viable eggs of their own, conventional IVF is not an option. For others, obtaining enough eggs requires hormone injections and egg retrieval surgery, often across multiple cycles.
What Ovelle is building
Ovelle is developing IVG to create eggs from a woman’s own cells, beginning with a blood draw or small tissue sample. Our goal is to create enough eggs from that single sample for all of a woman’s IVF attempts.
Meiosis induction in cells derived from human iPSCs. Image: Ovelle.
Why now
Advances in stem cell biology, developmental biology, computation, and high-throughput screening now allow us to systematically uncover how a human egg develops.
Ovelle combines these fields in a rapid cycle of prediction, testing, and learning to identify the biological instructions that guide cells toward becoming eggs.
Ovelle has developed technology to create ovarian cell types from human induced pluripotent stem cells and was the first company to produce meiotic oogonia-like cells. This is a key step toward creating eggs in the laboratory.
We are incorporating these cells into ovarian organoids designed to recreate the environment in which eggs grow and mature.
Read the research ↗Our vision
We believe IVG can become the new gold standard for producing eggs for IVF.
Our team
We bring together stem cell biology, developmental biology, computation, and cell engineering to solve one defining problem.
Every member of our team contributes directly to the mission.
Careers at Ovelle
We are looking for exceptional scientists who want to solve a difficult problem with direct human significance.
Explore careers
